Chesapeake Eye Care & Laser Center Llc | |
826 Washington Rd Ste 200, Westminster, MD 21157-5780 | |
(410) 876-3333 | |
Not Available |
Full Name | Chesapeake Eye Care & Laser Center Llc |
---|---|
Type | Facility |
Speciality | Ophthalmology |
Location | 826 Washington Rd Ste 200, Westminster, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1336790906 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | (* (Not Available)) | Secondary |
207W00000X | Ophthalmology | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Chesapeake Eye Care & Laser Center Llc 2002 Medical Pkwy Ste 320, Annapolis, MD 21401-7901 Ph: (410) 571-8733 | Chesapeake Eye Care & Laser Center Llc 826 Washington Rd Ste 200, Westminster, MD 21157-5780 Ph: (410) 876-3333 |
News Archive
Pioneering Spanish provinces in terms of early prevention of breast cancer, such as Navarre and the Basque Country, record lower death rates, although the trend is towards the figures levelling out all over Spain. These are the results of a study carried out by Spanish researchers, which analyses the number of women who died between 1975 and 2005.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a novel formulation of Pfizer's Neurontin that is dosed once a day would earn a 50 percent patient share in the treatment of postherpetic neuralgia, according to surveyed U.S. neurologists.
Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas - the most common form of brain tumor - suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
› Verified 6 days ago